Skip to main content
Top
Published in: Pathology & Oncology Research 1/2010

01-03-2010

Prognostic Factors and Survival of Renal Clear Cell Carcinoma Patients with Bone Metastases

Authors: Attila Szendrői, Elek Dinya, Magdolna Kardos, A. Marcel Szász, Zsuzsanna Németh, Katalin Áts, János Kiss, Imre Antal, Imre Romics, Miklós Szendrői

Published in: Pathology & Oncology Research | Issue 1/2010

Login to get access

Abstract

In our retrospective study the pathological and clinical factors, influencing the survival of 65 renal clear cell carcinoma patients operated for bone metastasis between 1990 and 2008 were examined. Based on Kaplan-Meier curves age, gender, clinical symptoms, pathological fracture, progression to the soft tissues, localization and size of the metastasis, whether the occurrence of multiplex metastases is multiorganic or only located to the skeletal system and the stage and grade of primary renal cancer did not influence the survival. The survival significantly improved if the bone metastases were solitary, low Fuhrman grade, late onset; and radical surgery was performed. Based on Cox regression analysis, survival after bone surgery was influenced by the multiplicity and grade of metastasis and by the radicality of the surgery, whereas survival after nephrectomy was significantly influenced by onset time and grade of metastasis. When the solitary metastasis was radically removed, 75.0% of the patients survived the first, and 35.5% the fifth postoperative year. If the metastasis was multiple or the surgery was not radical, no patient survived the fifth year. This is the first report on the prognostic significance of the Fuhrman grade of bone metastasis of renal cell cancer. While the Fuhrman grade of the primary tumour did not influence the survival, the lower grade of metastasis was associated with a significant longer survival. Therefore in cases of solitary, operable, late onset metastases with low Fuhrman grade radical removal is recommended, since this way in 35.5% of cases 5 year survival can be expected.
Literature
1.
2.
go back to reference Kozlowski JM (1994) Management of distant solitary recurrence in the patient with renal cancer. Urol Clin North Am 21(4):601–624PubMed Kozlowski JM (1994) Management of distant solitary recurrence in the patient with renal cancer. Urol Clin North Am 21(4):601–624PubMed
3.
4.
go back to reference Toyoda Y, Shinohara N, Harabayashi T et al (2007) Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 52(1):163–169CrossRefPubMed Toyoda Y, Shinohara N, Harabayashi T et al (2007) Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 52(1):163–169CrossRefPubMed
5.
go back to reference Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol 42:269–276 Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol 42:269–276
6.
go back to reference Fuchs B, Trousdale RT, Rock MG (2005) Solitary bony metastasis from renal cell carcinoma. Clin Orth Rel Res 431:187–192CrossRef Fuchs B, Trousdale RT, Rock MG (2005) Solitary bony metastasis from renal cell carcinoma. Clin Orth Rel Res 431:187–192CrossRef
7.
go back to reference Szendrői M, Sárváry A (2001) Surgery of bone metastases. In: Besznyák I (ed) Diagnosis and surgery of organ metastases, 1st edn. Akadémiai Kiadó, Budapest Szendrői M, Sárváry A (2001) Surgery of bone metastases. In: Besznyák I (ed) Diagnosis and surgery of organ metastases, 1st edn. Akadémiai Kiadó, Budapest
8.
go back to reference Han R, Pantuck AJ, Bui MHT et al (2003) Number of metastatic sites rather than location dictates overall survival of patients with node negative metastatic renal cell carcinoma. Urology 61:314–319CrossRefPubMed Han R, Pantuck AJ, Bui MHT et al (2003) Number of metastatic sites rather than location dictates overall survival of patients with node negative metastatic renal cell carcinoma. Urology 61:314–319CrossRefPubMed
9.
go back to reference Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg 89:1794–1801CrossRefPubMed Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg 89:1794–1801CrossRefPubMed
10.
go back to reference Althausen P, Althausen A, Jennings LC et al (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma cancer. 80:1103–1109 Althausen P, Althausen A, Jennings LC et al (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma cancer. 80:1103–1109
11.
go back to reference Kollender Y, Bickels J, Price WM et al (2000) Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 164:1505–1508CrossRefPubMed Kollender Y, Bickels J, Price WM et al (2000) Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 164:1505–1508CrossRefPubMed
12.
go back to reference Dürr HR, Maier M, Pfahler M et al (1999) Surgical treatment of osseous metastases in patinets with renal cell carcinoma. Clin Orthop Relat Res 367:283–290PubMed Dürr HR, Maier M, Pfahler M et al (1999) Surgical treatment of osseous metastases in patinets with renal cell carcinoma. Clin Orthop Relat Res 367:283–290PubMed
13.
go back to reference Swanson DA, Orovan WL, Johnson DE et al (1981) Osseous metastasis secondary to renal cell carcinoma. Urology 18:556–561CrossRefPubMed Swanson DA, Orovan WL, Johnson DE et al (1981) Osseous metastasis secondary to renal cell carcinoma. Urology 18:556–561CrossRefPubMed
14.
go back to reference Ficarra V, Righetti R, Martignoni G et al (2001) Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int 67(2):130–4CrossRefPubMed Ficarra V, Righetti R, Martignoni G et al (2001) Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int 67(2):130–4CrossRefPubMed
15.
go back to reference Minervini A, Lilas L, Minervini R et al (2002) Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 94(10):2590–2595CrossRefPubMed Minervini A, Lilas L, Minervini R et al (2002) Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 94(10):2590–2595CrossRefPubMed
16.
go back to reference Lang H, Lindner V, de Fromont M et al (2005) Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with > 15-year follow-up. Cancer 103(3):625–9CrossRefPubMed Lang H, Lindner V, de Fromont M et al (2005) Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with > 15-year follow-up. Cancer 103(3):625–9CrossRefPubMed
17.
go back to reference Ficarra V, Martignoni G, Maffei N et al (2005) Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 103(1):68–75CrossRefPubMed Ficarra V, Martignoni G, Maffei N et al (2005) Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 103(1):68–75CrossRefPubMed
18.
go back to reference Poel HG, Roukema JA, Horenblas S et al (1999) Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35:197–203CrossRefPubMed Poel HG, Roukema JA, Horenblas S et al (1999) Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35:197–203CrossRefPubMed
19.
go back to reference Onishi T, Ohishi Y, Iizuka N et al (1995) Study on the pathological grade in the primary and distant metastatic lesions of renal cell carcinoma. Hinyokika Kiyo 41(12):959–63PubMed Onishi T, Ohishi Y, Iizuka N et al (1995) Study on the pathological grade in the primary and distant metastatic lesions of renal cell carcinoma. Hinyokika Kiyo 41(12):959–63PubMed
20.
go back to reference Baloch KG, Grimer RJ, Carter SR et al (2000) Radical Surgery for the solitary bony metastasis from renal cell carcinoma. J Bone Joint Surg (Br) 82:62–67CrossRef Baloch KG, Grimer RJ, Carter SR et al (2000) Radical Surgery for the solitary bony metastasis from renal cell carcinoma. J Bone Joint Surg (Br) 82:62–67CrossRef
21.
go back to reference Adiga GU, Dutcher JP, Larkin M (2004) Characterisation of bone metastases in patients with renal cell cancer. BJU Int 93:1237–1240CrossRefPubMed Adiga GU, Dutcher JP, Larkin M (2004) Characterisation of bone metastases in patients with renal cell cancer. BJU Int 93:1237–1240CrossRefPubMed
22.
go back to reference Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Rel Res 409:223–231CrossRef Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Rel Res 409:223–231CrossRef
Metadata
Title
Prognostic Factors and Survival of Renal Clear Cell Carcinoma Patients with Bone Metastases
Authors
Attila Szendrői
Elek Dinya
Magdolna Kardos
A. Marcel Szász
Zsuzsanna Németh
Katalin Áts
János Kiss
Imre Antal
Imre Romics
Miklós Szendrői
Publication date
01-03-2010
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9184-7

Other articles of this Issue 1/2010

Pathology & Oncology Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine